CADTH Canadian Drug Expert Committee, & Canadian Agency for Drugs and Technologies in Health. (2017). CADTH Canadian Drug Expert Committee recommendation: AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.): Indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults (Version 1.0.). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health.
Chicago Style CitationCADTH Canadian Drug Expert Committee, and Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: AbobotulinumtoxinA (Dysport Therapeutic -- Ipsen Biopharmaceuticals Canada Inc.): Indication: For the Symptomatic Treatment of Focal Spasticity Affecting the Upper Limbs in Adults. Version 1.0. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017.
MLA CitationCADTH Canadian Drug Expert Committee, and Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug Expert Committee Recommendation: AbobotulinumtoxinA (Dysport Therapeutic -- Ipsen Biopharmaceuticals Canada Inc.): Indication: For the Symptomatic Treatment of Focal Spasticity Affecting the Upper Limbs in Adults. Version 1.0. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017.